We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Infrared Light Technology May Open New Opportunities to Image Cancer, Tay Sachs Disease

By LabMedica International staff writers
Posted on 28 Sep 2010
A technique employing near-infrared light enables scientists to look deeper into the workings of cells, potentially creating a new tool in the fight against cancer and many other diseases.

University of Central Florida (UCF; Orlando, USA) chemists, led by Prof. More...
Kevin Belfield, used near infrared light and fluorescent dye to take pictures of cells and tumors deep within tissue. The probes specifically target lysosomes, which have been linked to a variety of diseases, including types of mental illnesses and cancers.The probes can be adapted to look for specific proteins found in tumors, which means they someday may help physicians diagnose and potentially treat tumors. "This is a game-changer,” Prof. Belfield said. "Until now, there was no real way to study lysosomes because existing techniques have severe limitations. But the probe we developed is stable, which allows for longer periods of imaging.”

Conventional imaging probes work for only a few minutes. They cannot penetrate deep tissue, are sensitive to pH levels, and have poor water solubility. Prof. Belfield's technique jumps over those hurdles by using near-infrared light. Once researchers identified the correct light frequency, they took images of lysosomes for hours. The new approach will allow researchers to see lysosomes at work and to piece together their role in diseases such as cancer and Tay-Sachs, a genetic disorder from which children typically die by age four.

"We've come up with something that should make a huge difference in finding answers to some very complicated conditions,” Prof. Belfield concluded.

The study's findings, which include comparisons to the only two existing probes on the market today, were published in the August 2010 issue of the Journal of the American Chemical Society.

Related Links:

University of Central Florida




Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.